PAR 3.92% 24.5¢ paradigm biopharmaceuticals limited..

If PAR's strategy was to await the outcome of the MPS trial, why...

  1. 2,135 Posts.
    lightbulb Created with Sketch. 573
    If PAR's strategy was to await the outcome of the MPS trial, why did they ask for term sheets over a year ago?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.